Group 1: Transaction Overview - The transaction with Defo Capital involves the transfer of 8.09% equity from the original controlling shareholder and the acquisition of 95.5% equity in Beijing Jinkangpu, aimed at vertical integration in the industry [3][4] - The acquisition is expected to enhance the company's capabilities in customer service, channel diversification, and resource integration, providing strong support for future development [2][3] Group 2: Strategic Alignment - Defo Capital's focus on the health sector aligns with the company's strategic direction, recognizing the potential in natural health components [4][5] - The company has over 20 years of industry experience, a robust production capacity, and a comprehensive quality control system, making it an attractive partner for Defo Capital [5][6] Group 3: Business Development Plans - The company plans to focus on two main directions for its synthetic biology business: developing proprietary products and providing industrialization services for external clients [6][7] - The RM2 product, a key natural sweetener, is expected to reshape the market, with plans for promotion through high-quality product and formulation services [7][8] Group 4: Capacity and Utilization - The company has established multiple extraction facilities, ensuring sufficient capacity, but current utilization rates are low due to new facilities not yet being operational [8][9] - Future capacity release will depend on sales growth of core products and the introduction of new synthetic biology products into the market [9][10] Group 5: Global Operations - The upgrade of the U.S. extraction facility aims to enhance supply chain security and meet global customer demands, focusing on producing raw materials advantageous in North America [9][10] - The company plans to optimize overseas capacity and improve product delivery efficiency to achieve significant operational improvements in the U.S. market [9]

Core Viewpoint - The control of Rhein Biotech (002166.SZ), known as the "first stock of plant extraction," will be transferred to Guangzhou Defu Nutrition, led by the well-known investment institution Defu Capital, alongside a strategic acquisition of 80% of Beijing Jinkangpu, a company specializing in food nutrition fortifiers [2][3]. Group 1: Company Overview - Rhein Biotech is a leading player in the global plant extraction industry, with over 20 years of experience in natural sweeteners, holding a significant market share in stevia and monk fruit extracts [3]. - The company has recently achieved a major milestone with its synthetic biology technology, which is expected to generate over 1 billion yuan in annual output once its first domestic production line reaches full capacity [3]. Group 2: Financial Performance - Despite revenue growth, Rhein Biotech's net profit attributable to shareholders decreased by 30.73% year-on-year in the third quarter of 2025, highlighting the industry's challenges of intensified competition and price pressure [3]. Group 3: Strategic Moves - The acquisition by Defu Capital is not merely a financial investment but aims to vertically integrate the industry chain by acquiring control and injecting assets to fill Rhein Biotech's downstream gaps [4]. - The injected asset, Beijing Jinkangpu, is a leader in the food nutrition fortifier sector, providing a strategic intent to create an industry closed loop, allowing Rhein Biotech's upstream natural extracts to supply high-value nutrition fortifiers and end products [4]. Group 4: Future Outlook - Post-acquisition, Rhein Biotech's development path is clear, with short-term synergies expected to enhance profitability and risk resilience [5]. - In the medium to long term, the company will transition from a single plant extract supplier to a comprehensive platform covering "natural raw materials—core ingredients—end formulations," expanding into broader health and nutrition sectors [5]. - The success of this integration will determine whether Rhein Biotech can navigate through cycles and secure a more significant position in the global health industry [5].

Core Viewpoint - Rhein Biotech, a leader in the plant extraction industry, is undergoing a significant change in control and asset acquisition, led by Defu Capital, which manages over $34 billion in funds, aiming to inject strong growth momentum into the company [1][2]. Group 1: Company Overview - Rhein Biotech has over 300 standardized plant extraction technologies and has established multiple national-level research platforms, including a "National Tropical Fruit Processing Technology R&D Center" and a "Postdoctoral Research Station" [1]. - The company holds a stable global market share of 20%-25% in monk fruit extract and ranks among the top three globally in stevia extract sales [1]. Group 2: Capital Cooperation - Defu Capital, a seasoned investment institution in the healthcare and consumer sectors, is acquiring control through its Guangzhou Defu Nutrition Investment platform, with 99.926% of the investment coming from its core operating entity, reflecting strong confidence in Rhein Biotech's future [2]. - The acquisition includes Beijing Jinkangpu Food Technology Co., a leading company in the food premix sector, which has three modern production bases and a capacity of over 10,000 tons [2]. Group 3: Strategic Synergy - The collaboration between Rhein Biotech and Jinkangpu is expected to create a robust industrial ecosystem, where Rhein's natural raw materials will supply Jinkangpu's production system, ensuring quality raw materials for end products [2]. - Jinkangpu's strong customer base and international channels will open new markets for Rhein's high-value products, enhancing product value significantly [2]. Group 4: Future Prospects - The partnership is anticipated to accelerate the transformation of technology for Rhein Biotech, integrating its R&D capabilities with Jinkangpu's application strengths in food and health products [3]. - As consumer demand for "natural health" continues to rise, this strategic alliance is expected to further solidify Rhein Biotech's leading position in the global natural health products market [3].

Core Viewpoint - Guilin Rhein Biotech Co., Ltd. reported a sales revenue growth of over 15% in the first half of 2025, but profits were under pressure due to industry competition, increased depreciation, and tariffs [1]. Group 1: Business and Performance - The company’s sales revenue growth exceeded 15% in the first half of 2025, but profits faced challenges from competitive pressures, rising depreciation costs, and tariffs [1]. - The company’s Vice General Manager and Board Secretary, Luo Huayang, participated in an online communication with nine institutions, including Zheshang Securities and Tianfeng Securities, to discuss operational performance [1]. Group 2: Raw Material and Product Price Trends - The purchase price of monk fruit raw materials is expected to remain stable this year, while the price of stevia raw materials is anticipated to be similar to last year [2]. - Some specifications of stevia products have seen slight price declines due to industry competition, but raw material costs are expected to support price stability [2]. - The price of monk fruit extracts is projected to rise as raw material prices recover [2]. Group 3: Product Development and Market Position - Rhein Biotech holds exclusive technology for the industrialization of stevia glycoside RM2, which is noted for its good taste, compatibility, and relatively controllable costs [2]. - The domestic certification for RM2 is dependent on government approval, while it has already received GRAS certification from the FDA in the U.S. and is in discussions with clients for cooperation [2]. - The company expects its synthetic biology workshop capacity to meet market demand within the next 2-3 years [2]. Group 4: Industrial Hemp Business - Despite potential policy adjustments regarding hemp by the U.S. President, there has not been a significant market recovery [2]. - The Indiana factory has been transformed into a comprehensive extraction facility, and the company will actively follow up if demand for industrial hemp revives [2]. Group 5: Competitive Advantages and Future Outlook - Rhein Biotech enhances its competitiveness through technological innovation and expanding application scenarios, particularly in synthetic biology and emerging markets like pet nutrition [2]. - The utilization rate of the new stevia extraction factory is expected to reach 40-50% for the year, with a significant increase anticipated after new raw materials are launched in September [2]. - The Indiana factory is positioned to navigate complex trade environments, focusing on natural sweeteners and leveraging local raw material procurement for supply chain security [2]. - The company anticipates a positive shift in operational performance in the third and fourth quarters of 2025, as trade policy uncertainties diminish and new products are launched [2].

Group 1: Raw Material Prices and Trends - The acquisition prices for core products, Luo Han Guo and Stevia, are expected to remain stable this year due to stable planting areas and yields [2][3] - The price of Stevia products has slightly decreased due to increased competition, but this is viewed as a short-term trend as raw material costs have limited downward potential [3][4] - Luo Han Guo extract prices are anticipated to rise further based on raw material price fluctuations [4][6] Group 2: RM2 Product Overview - RM2 is a unique steviol glycoside that offers superior taste, stability, and solubility compared to existing products like RD and RM [4][6] - RM2 has excellent compatibility with other sweeteners, allowing for diverse applications in baking and other food products [4][6] - The production cost of RM2 is controllable due to the advantages in raw material production, providing a cost advantage over traditional extraction methods [4][6] Group 3: Market Position and Competitive Advantage - RM2 is currently exclusive to the company, with significant barriers for competitors due to the need for specific technology and lengthy safety reviews [6][10] - The company has made substantial progress in product development and market expansion, particularly in emerging markets like pet nutrition and animal feed [10][11] - The company aims to leverage continuous innovation and differentiation to maintain a competitive edge in the natural sweetener market [10][11] Group 4: Production Capacity and Future Outlook - The new production facility in Indiana is expected to meet market demand over the next 2-3 years, with production capacity utilization projected to reach 40-50% by year-end [11][12] - The company anticipates a sales revenue growth of over 15% in the first half of the year, despite pressure on profits from competition and tariffs [12] - The outlook for the second half of the year is optimistic, with expectations of improved operational conditions as new products are launched [12]